Hepatocellular Carcinoma: Consider India For Your Next HCC International Trial

By Poltanov, Evgeny MD, PhD, Director of Eastern European Operations, Biorasi; Kelji, Akshay MS, Feasibility Manager, Biorasi; and Panigrahi, Rachana MSc, Feasibility Specialist II, Biorasi.

An unmet medical need in hepatocellular carcinoma (HCC) has led to a significant increase in the number of global clinical trials and new therapies for the disease. HCC is the most common type of liver cancer globally and is the third most common cause of cancer-related death in the Asia-Pacific region.⁹ Due to its severity and low survival rate, the overall unmet medical need in HCC remains high. New therapies enter the market each year, focused on improving the survival rate. However, despite the involvement of countries in the Asia-Pacific region, the number of HCC clinical trials conducted in India remains low.

In this white paper, the authors discuss the viability of India as a potential venue for HCC trials as well as its epidemiology, historical perceptions, and untapped potential for international clinical research opportunities.